Terms: = Ovarian cancer AND PCSK7, Q16549, 9159, ENSG00000160613, PC8, SPC7, PC7, LPC
28 results:
1. Lipidomics and pancreatic cancer risk in two prospective studies.
Naudin S; Sampson JN; Moore SC; Albanes D; Freedman ND; Weinstein SJ; Stolzenberg-Solomon R
Eur J Epidemiol; 2023 Jul; 38(7):783-793. PubMed ID: 37169992
[TBL] [Abstract] [Full Text] [Related]
2. Results of ovarian Sparing Surgery in Pediatric Patients: Is There a Place for Laparoscopy?
Guillén G; Martín-Giménez MP; López-Fernández S; Molino JA; López M
J Laparoendosc Adv Surg Tech A; 2020 Apr; 30(4):458-463. PubMed ID: 32013689
[No Abstract] [Full Text] [Related]
3. LDLR-mediated lipidome-transcriptome reprogramming in cisplatin insensitivity.
Chang WC; Wang HC; Cheng WC; Yang JC; Chung WM; Ho YP; Chen L; Hung YC; Ma WL
Endocr Relat Cancer; 2020 Feb; 27(2):81-95. PubMed ID: 31815680
[TBL] [Abstract] [Full Text] [Related]
4. Circulating Lysophosphatidylcholines, Phosphatidylcholines, Ceramides, and Sphingomyelins and ovarian cancer Risk: A 23-Year Prospective Study.
Zeleznik OA; Clish CB; Kraft P; Avila-Pacheco J; Eliassen AH; Tworoger SS
J Natl Cancer Inst; 2020 Jun; 112(6):628-636. PubMed ID: 31593240
[TBL] [Abstract] [Full Text] [Related]
5. Mass spectrometric discrimination of phospholipid patterns in cisplatin-resistant and -sensitive cancer cells.
Cadoni E; Vanhara P; Valletta E; Pinna E; Vascellari S; Caddeo G; Isaia F; Pani A; Havel J; Pivetta T
Rapid Commun Mass Spectrom; 2019 Jan; 33(1):97-106. PubMed ID: 30376198
[TBL] [Abstract] [Full Text] [Related]
6. Synthesis and Activity of a Novel Autotaxin Inhibitor-Icodextrin Conjugate.
Fisher N; Edwards MG; Hemming R; Allin SM; Wallis JD; Bulman Page PC; Mckenzie MJ; Jones SM; Elsegood MRJ; King-Underwood J; Richardson A
J Med Chem; 2018 Sep; 61(17):7942-7951. PubMed ID: 30059212
[TBL] [Abstract] [Full Text] [Related]
7. Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial ovarian cancer.
Zhou M; Li L; Wang X; Wang C; Wang D
Cell Physiol Biochem; 2018; 46(1):178-186. PubMed ID: 29587273
[TBL] [Abstract] [Full Text] [Related]
8. Laparoscopy for primary cytoreduction with multivisceral resections in advanced ovarian cancer: prospective validation. "The times they are a-changin"?
Ceccaroni M; Roviglione G; Bruni F; Clarizia R; Ruffo G; Salgarello M; Peiretti M; Uccella S
Surg Endosc; 2018 Apr; 32(4):2026-2037. PubMed ID: 29052073
[TBL] [Abstract] [Full Text] [Related]
9. Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for ovarian cancer.
Lee JH; Kim YH; Kim KH; Cho JY; Woo SM; Yoo BC; Kim SC
Cancer Res Treat; 2018 Jul; 50(3):883-893. PubMed ID: 28934848
[TBL] [Abstract] [Full Text] [Related]
10. Relations between GPR4 expression, microvascular density (MVD) and clinical pathological characteristics of patients with epithelial ovarian carcinoma (EOC).
Ren J; Jin W; Gao YE; Zhang Y; Zhang X; Zhao D; Ma H; Li Z; Wang J; Xiao L; Liu R; Chen Y; Qian J; Niu L; Wei H; Liu Y
Curr Pharm Des; 2014; 20(11):1904-16. PubMed ID: 23888957
[TBL] [Abstract] [Full Text] [Related]
11. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells.
Gaetano CG; Samadi N; Tomsig JL; Macdonald TL; Lynch KR; Brindley DN
Mol Carcinog; 2009 Sep; 48(9):801-9. PubMed ID: 19204929
[TBL] [Abstract] [Full Text] [Related]
12. Lysophospholipid signaling in the function and pathology of the reproductive system.
Ye X
Hum Reprod Update; 2008; 14(5):519-36. PubMed ID: 18562325
[TBL] [Abstract] [Full Text] [Related]
13. Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer.
Page RE; Klein-Szanto AJ; Litwin S; Nicolas E; Al-Jumaily R; Alexander P; Godwin AK; Ross EA; Schilder RJ; Bassi DE
Cell Oncol; 2007; 29(4):289-99. PubMed ID: 17641413
[TBL] [Abstract] [Full Text] [Related]
14. Human resting CD16-, CD16+ and IL-2-, IL-12-, IL-15- or IFN-alpha-activated natural killer cells differentially respond to sphingosylphosphorylcholine, lysophosphatidylcholine and platelet-activating factor.
Jin Y; Damaj BB; Maghazachi AA
Eur J Immunol; 2005 Sep; 35(9):2699-708. PubMed ID: 16078278
[TBL] [Abstract] [Full Text] [Related]
15. Bioactive lysophospholipids and mesangial cell intracellular signaling pathways: role in the pathobiology of kidney disease.
Kamanna VS; Bassa BV; Ganji SH; Roh DD
Histol Histopathol; 2005 Apr; 20(2):603-13. PubMed ID: 15736064
[TBL] [Abstract] [Full Text] [Related]
16. G2A is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine.
Murakami N; Yokomizo T; Okuno T; Shimizu T
J Biol Chem; 2004 Oct; 279(41):42484-91. PubMed ID: 15280385
[TBL] [Abstract] [Full Text] [Related]
17. Lysophospholipids are potential biomarkers of ovarian cancer.
Sutphen R; Xu Y; Wilbanks GD; Fiorica J; Grendys EC; LaPolla JP; Arango H; Hoffman MS; Martino M; Wakeley K; Griffin D; Blanco RW; Cantor AB; Xiao YJ; Krischer JP
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1185-91. PubMed ID: 15247129
[TBL] [Abstract] [Full Text] [Related]
18. The G protein-coupled receptor GPR4 suppresses ERK activation in a ligand-independent manner.
Bektas M; Barak LS; Jolly PS; Liu H; Lynch KR; Lacana E; Suhr KB; Milstien S; Spiegel S
Biochemistry; 2003 Oct; 42(42):12181-91. PubMed ID: 14567679
[TBL] [Abstract] [Full Text] [Related]
19. Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells.
Fu Y; Campbell EJ; Shepherd TG; Nachtigal MW
Mol Cancer Res; 2003 Jun; 1(8):569-76. PubMed ID: 12805404
[TBL] [Abstract] [Full Text] [Related]
20. Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction.
Xu Y
Biochim Biophys Acta; 2002 May; 1582(1-3):81-8. PubMed ID: 12069813
[TBL] [Abstract] [Full Text] [Related]
[Next]
